

;3,9#!O 89 9#805&O#7, O  
#&57#O 9\*#O\$ "#8 ,c<8 !#c 2-.;;(2/c

+JMOBO  
"6( 142 G2 O% D2FLBO O

C4121

3#<(<(2/c2o6= ;&c  
(?,d/?#;<(% <(?!#- /!c ! <#!c+=,Ac c c

N37K... 47... <3 ÔÎ<3Ôn  
M+7.±;& &F<<77-

C Y >9 O  
h ,  
> \$+ "h  
4i h  
. > h

M 9 ,  
N 4  
! h + ÔN  
N \$ h  
4i h  
.i h

\$bbY] DfY&D [N:T-YW> h

& C9O h "h

-ÿ>73 .

4+>7Æ.YF;4A:4.

3 3 ..... h  
33m . - > E h h  
333 + ..... h  
+ 4 Y \3 A"" A Ù +  
. Y + Y . Y ..... h  
>B Y I , "ê+ \$Y3& E 3 " <  
+ , L K " A 3 - 7 \*  
+ Y ..... h  
/ O Y ..... h

4 + > 7 AF . + @ 4 MF < 2 4 2 A ,

\_\_\_\_\_

\$ 0 : 0 0 % b T ; W R Q S & D Y T h @ h  
/ ) ( . ! 0 ) % &

\_\_\_\_\_

Regulations

( c (T[YUF]D[KUTc

- / @ , P/( G% ) .BHP!B(% ' 2 %R D'

b 2 & . 4

% R D' C ( ! 0%R! Ø&D' . •

\* p - ø2" p

< "- \* \*

" g . 9à : ! ? 4 \*

L

4 b ! 0 2& "

\ - 0 @• À gñÂ(•ÓÔ @ p(p(p c Ó p°!AAQ]AOc AQFc 5 Z zaÚ ñ1<lg "


[REDACTED]

[REDACTED]

[REDACTED]

" \ \* E ~

, g 7 + \* \$ 4 \$2 %+ !\$  
! )'% R O ç , O D' % .4 GA, ç G! .4 (GAç ! )! Á  
+œ + : ! )< \$ ""  
\* r " - ø 2 2ö ý î Û \$  
" \$ a o Z+(S&+(O



<sup>3</sup> Cephalon's patent settlements with Teva, Ranbaxy, Mylan, Barr, and Carlsbad atson are collectively referred to as the "Provigil Settlements."

<sup>4</sup> Redacted

F . :\$! ?\$ I @  
, & " & \$ \*  
" I G I " / " . 4  
+ %R.4+ D\*\$@ , B/ .4 - v ?/ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

F + !? \$ ?\$ > ' " \  
@ , & " A & "-  
! ? @ , P 5 5 % 5 D B h & E ; 5 \$ ? ! 5 5 % & & F K  
! \$ ! ? \$ p K &  
\$ ; \$ ? ! 5 % A & ' \$ \ R L W : K T T D R O V h ! 5 5 % & & 4 '  
~ " " + 9 " " C n  
% \* \* " ' " C ! ? \$ 0 F & E ;  
! \$ ? ! 5 % & - '

F C ( ! 0 \$ " " ! 0 2 & \$ ~ "

[REDACTED] 15 D D h a K E 9 M K \$ & . 4 \$ \$

C > N \$ - E M & 77-% C ( ! 0 %

@ 10 E " \* [REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

" 5 G

Z+(S&+(O

[Redacted]



(( ( c YI]RGT[c

c <JGU R R K Z Z K ( U T G Z [ K I B [ H U G D [ # T E G O d G [ J b G t G T D \$ k O B F c  
U R X O B K B [ k T Z Q X J B O U \$ G K G Y B O c U ] Y [ c

4 " © 9 "

" L —Redacted

[Redacted]

[Redacted] . 2 " \* b

E "

4 .4 + " % 2 & '

9£ L n ! "•

.4 + =G Y \ D h 9 "

} %o@ , P/( G %%! 0% ' T T

" a :Cd @ R > : b R Y W h 4 + • " \* /

@ , HP/( G, ' %! 0% ' H2 u

R @D 9 L 9 + D W d R: W d h

] / G

- @ > 72



v. \$: o 55/.B! :?!\$ :? ?%/ 0( ' 5 D DTh` 8 W R 5 D : @ D \$ h` Y > R : b D @ h  
1 D \ > O : W @ & R Y R W L h , // : \$ / ? % & B B ; B ) ) % w % 2 L 9 \$  
\$ o B . D W j W v . O O h : \ > O D h  
: ) : @ , 5 B \$ 5 % 0 ) % \ w 9 \* \*  
L D ' h j : W @ 2 R @ Y . h \$ : o 5 ( / .  
, ! ) \$ ! ) ? % ; & 2 0 % 0 ' H j D W D 1 \ Y T Y & Y \ j . h 7 ' h B ( ( G ( ) \$ ( ( (   
N 7 // ! % ; & F B ; 5 \$ 0 ( ( % Â  
4 \ \* \$ . 4 + \$  
" o è , B , : W W : O : h @ , B 5 5 ) j  
\$ : o v . \$ b T : W R R > P H & D T Y @ h ! 0 ) \$ ! % & B 0 ( ( % w j Ú <  
E } L i " \$  
Ä @ p q s o m d w e r # d @ P H I \$ ' X A Ê P ß C a p Õ ß Q ß & X E à ß 4 \ À p





1 - , g 1 1 b 1 1 •  
? 2  
1 1 € ! ( , 1  
œ 1 1 1" 1 1"  
& "N + 4 % R 4 & D !  
F + ! ) ! ( 1 1 1 2 1 &  
% R ! & D ; " \* 5 0 1 1 1 hÁD` P - 8šĐ IA† , t pĐeÀ` à

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

<sup>7</sup> The 2007 Subpoena defined the settlements and business transactions jointly as "Generic Agreements"—a  
Redacted  
Redacted  
Redacted  
Redacted  
Redacted

= ('# £ 8< C E E :55i ]:(:š=V D(H[N:TYWW>K hd ;

) ?=%` =k =0= (' € 88

Z+(S&+(O

88b 10

4 P L • = 03&

\* I b \* 8 .

= 03&T E E K / = (r 8

I = 03& 3 9 K = 03&

8

\* \* 8 ±

< K

E \* E \* \* 8

I . 9I = ?

5 D Del[ \ :-H - O

3 8 I 8

I ä

4 88

documents bearing bates numbers with  
See Osbor Tr., 390:1-5; Zakreski Tr.,  
f om Cephalon's production, Cephalon

Ž, (S&, (O

Ž, (S&, (O

[Redacted line]

[Redacted] . t a k > N - E  
M & tt-\$ - K A , > . 4 % F =: \$ (.

[Redacted line]

[Redacted line], 88

\* 8  
= ?; \* Q \* \$  
. < 8 -  
00 d\$ 88 \* b 88 \*  
\$ L

G x

. O UTEP]ZKUTc

. W # # • # W #

W #J,, 3 & m̄

| 37\_A < @ 7 A < - 3 { A < 3 ; n  
M + 7 A ; & & † < < 77 -

*H. Likier*

k Y # > •  
U J, W y W # # # W  
> W \_ + J ! J ,,  
e z U ( " / ! U ] U J J J  
. š U ( f / ! U ^ / J J J

M W , V # #  
| # e #  
? ( / - # + # | #  
| • W & ! J J J U  
e Q J ! f U U : ^ U J J J  
. z ! J ! ] U U : ^ U : U :

\$ c Y ] D f a y n ( H D [ N : U Y W W > h h

& W # k z ! X ! J J ,,

11 To the extent this CI seeks the production of documents or the disclosure of information subject to attorney-client privilege, work product doctrine, or joint defense/common interest doctrine, Cephalon also objects, and reserves its right to assert these privileges if and when required to respond to this CI .

] ]

## **APPENDIX - PUBLIC VERSION**

=/(("<"c;<"<"2\$c-"8( c  
"\$28" c<&"\$!"7 ,c<7 !"c 2--(;;(2/c


(S G c

"3& ,c2/ d/ c\$LGd c c

"7<(\$(<"c2\$c"7?("c0!c2\$c >8 Ac 2\$c," <72/( c 2W`c

3\$ld , \$ d 8 3 86006\*6 6  
Q \$ B \$\* †8Q8 , 168 .é e 6 66 X<sup>A</sup>h  
6& \$ "#hφ 6 \* 16 68 6 Q 668 6 \$  
3 -\ 66† 3 & & k h "h 6•d + ® T  
ï6 O \$R- 6 %Dφ 6 O h6 68 668  
- 6 È% φ & \* O 6 668 6 Q O - 6 \$ \*  
6 9 â6 6 68 • 6 + O- b 68 , S  
6 668 - 6 G 6& Eí" m 66

N 3\_A< @ e A<- 3 {A<3;nM+7A+ ;&  
&†<<77-



M •d ,  
! h û ü + \$N  
N d6&\$ h  
h h

\$cY\W D NaID [N:UYW h-W? h

& È h "h





" fi1! "° Ø! !~žŒ, O / "ł i' O  
~ " , fi1 " O ~ " Q " !" 8 , c < 7 !" c 2 -- ( ; ; ) 2 / c

+ JMB O

" 6 ) 4 2 O + 2 % D2GLB O O

REQUEST \$ 27 c 2 / \$ ( ! " / < ( , c < 7 " < - " / < c



=/(("<" ;c;< <" ;c2 \$c-"7( c  
"\$27"c<&"\$!"7 ,c <7 !"c 2--(;;(2/c

(SvGc  
"3& ,2/ c(/ c \$LGVc c

; < <" -"/<c ~~REDACTED~~ A c c \$ 7/c (c)

Õ C ! S 0\$ # > fN # #c -#cM # Z•ë77-

%RN # M #D'S # \$ %R # °'S -# # # #§ #>

\_+ fi # fN #M # , c >c %Z# + Z c# c #

ð ~~FOIPA~~

Burling



=1(<" ;c ;< <" ;2\$c -"8( c  
"\$27"c <"c\$!"7 ,c <7 !"c 2--(;;(21c

(TÿGc  
"3' ,21 c (1 cLGtUycÄ—y—Ä™d

!" , 9<(21c 2\$c@ "1!Acα"87A¢1c=3327<2\$c  
c3"<(<(21c2c  
(? (.c(1?!"<(% <(? "d-1!c! <"!c += Ac™yyÄ

3 + 4 \$ b \$ 9 8 L9 \$ 9 X?@ , P h5)É  
3 9 O \* << 8N O 9 O- E M O &•i77-\$  
8 O \$ %[ D3 8 > 8  
& ' 8 9 \$ - ‡9 3 3 E & & C\$X 0  
9 d8

X


: 9 9 9 9 QT \* d 3  
\$ \* 9 8 9 9 ,MA{ `A

5 F K : \$X h\$ , l x: 8 3 &  
("CID") + X)\$ h\$ 8 9 L\*' #%' O  
including , 9 \$.4 x X) X' X' O€

5 0Ä m@æ  
à +

hs F C : \$= h \$response Specification / " 3 & \$ Ž Ž  
" the **Redacted** .

3  
E \* AT "p L " 9  
ò = ù "C \$ 0 "



C == \$ 0











**REDACTED - NON-PUBLIC**





